Showing results (381-390 of 534) with videos related to
Sort By:
Pageof 54
Journal of Cardiovascular Pharmacology|December 23, 2004
Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury modelKai Wang, Khaldoun Tarakji, Zhongmin Zhou, et al.Archives of Cardiovascular Diseases|August 12, 2009
Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trialJean-Philippe Collet, Gilles Montalescot, Philippe Gabriel Steg, et al.Genome Biology|March 31, 2009
Evaluation of next generation sequencing platforms for population targeted sequencing studiesOlivier Harismendy, Pauline C Ng, Robert L Strausberg, et al.American Heart Journal|August 9, 2005
The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trialSorin J Brener, A Michael Lincoff, Eric R Bates, et al.Circulation|June 12, 2002
Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-upMarco Roffi, David J Moliterno, Bernhard Meier, et al.Circulation|November 26, 2009
Smoking, clopidogrel, and mortality in patients with established cardiovascular diseaseJeffrey S Berger, Deepak L Bhatt, Steven R Steinhubl, et al.Heart Rhythm O2|June 11, 2021
Healthcare resource utilization following ECG sensor patch screening for atrial fibrillationJill Waalen, Alison M Edwards, Anirudh Sanyal, et al.JACC. Cardiovascular Interventions|October 24, 2009
Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitalsHoward C Herrmann, Jiandong Lu, Bruce R Brodie, et al.Journal of the American College of Cardiology|September 19, 2003
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trialMitchell J Ross, Howard C Herrmann, David J Moliterno, et al.Circulation|June 3, 2010
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialPeter B Berger, Deepak L Bhatt, Valentin Fuster, et al.Pageof 54